Across TCGA pan-cancer cohorts, ITPA Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ITPA data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ITPA Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ITPA expression acts as an unfavorable survival marker.
LUSC and SKCM are the cancer types where ITPA Mutation most reproducibly stratifies survival.